7 results
Summary of characteristics of Antianginal Drugs

DRUG CLASS, ADVERSE EFFECTS 
 AND DRUG 
INTERACTIONS 

#Antianginal #Medications #Cardiology
Summary of characteristics ... INTERACTIONS ... #Antianginal #Medications ... #Cardiology #Pharmacology ... Management #Therapy #Table
Summary table of mechanism of action, side effect and contraindications of commonly used diabetic drugs. 

#pharmacology
Summary table of ... commonly used diabetic ... drugs. ... #pharmacology #dm2 ... #diabetes #medications
Summary of Diuretic Agents 
Subclass, Drug, Mechanism of Action, Effects, Clinical Applications, Pharmacokinetics, Toxicities, Interaction
CARBONIC ANHYDRASE
Agents Subclass, Drug ... Pharmacokinetics, Toxicities, Interaction ... #Diuretics #Medications ... #Pharmacology # ... summary #table #
DPP-4 Inhibitors - Pharmacology Summary
Mechanisms of Action: Inhibits DPP-4 (dipeptidyl peptidase 4), which normally inactivates GLP-1
4 Inhibitors - Pharmacology ... Summary Mechanisms ... peptidase 4), which normally ... #Summary #DM2 # ... diabetes #endocrinology
GLP-1 Receptor Agonists - Pharmacology Summary
Mechanisms of Action: Stimulate glucose-dependent insulin release from the pancreas (GLP-1
Receptor Agonists - Pharmacology ... Summary Mechanisms ... Glucagon-like peptide 1; normally ... Ozempic), or daily tablet ... diabetes #endocrinology
DPP4 Inhibitors - Normal and Renal Dosing

Increase Incretins (GLP-I & GIP) -> Stimulates Insulin, Inhibits Glucagon
DPP4 Inhibitors - Normal ... This drug class ... Renal #Dosing #Pharmacology ... #Management #Diabetes ... #DM2 #Endocrinology
Rybelsus (oral semaglutide) - First Oral GLP-1 Agonist
Dosing:
3 mg daily x 30 days, then 7 mg
semaglutide, the same medication ... to remain stable ... #semaglutide #Diabetes ... #Pharmacology # ... Endocrinology